TScan Therapeutics, Inc. SEC filings TCRX

TScan Therapeutics, Inc. has 334 filings in SEC EDGAR's recent list, going back to Jul 26, 2019. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (officer or director change). The company's fiscal year ends on December 31.

Form Description Filed Period
DEF 14A Proxy statement Oct 26, 2026 Nov 20, 2026
PRE 14A Preliminary proxy statement Oct 16, 2026 Nov 20, 2026
DEF 14A Proxy statement Apr 17, 2026 May 20, 2026
PRE 14A Preliminary proxy statement Apr 7, 2026 May 20, 2026
DEFA14A Additional proxy material May 14, 2025 —
DEF 14A Proxy statement May 14, 2025 Jun 30, 2025
DEFA14A Additional proxy material Apr 30, 2024 —
DEF 14A Proxy statement Apr 30, 2024 Jun 12, 2024
DEFA14A Additional proxy material Jun 2, 2023 —
DEFA14A Additional proxy material Apr 25, 2023 —
DEF 14A Proxy statement Apr 25, 2023 Jun 13, 2023
DEFA14A Additional proxy material Apr 21, 2022 —
DEF 14A Proxy statement Apr 21, 2022 Jun 1, 2022

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
TCRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
, Emerging growth company
SEC CIK
1783328

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.